Jiafen Hu Selected Research

Papilloma (Papillomatosis)

1/2021	The environmental pollutant and tobacco smoke constituent dibenzo[def,p]chrysene is a co-factor for malignant progression of mouse oral papillomavirus infections.
8/2014	Formulation of cidofovir improves the anti-papillomaviral activity of topical treatments in the CRPV/rabbit model.
1/2014	Long-peptide therapeutic vaccination against CRPV-induced papillomas in HLA-A2.1 transgenic rabbits.
9/2009	Papillomavirus DNA complementation in vivo.
8/2008	CRPV genomes with synonymous codon optimizations in the CRPV E7 gene show phenotypic differences in growth and altered immunity upon E7 vaccination.
12/2007	Detection of L1, infectious virions and anti-L1 antibody in domestic rabbits infected with cottontail rabbit papillomavirus.
1/2007	Increased immunity to cottontail rabbit papillomavirus infection in EIII/JC inbred rabbits after vaccination with a mutant E6 that correlates with spontaneous regression.
1/2006	Protective cell-mediated immunity by DNA vaccination against Papillomavirus L1 capsid protein in the Cottontail Rabbit Papillomavirus model.
1/2005	Large cutaneous rabbit papillomas that persist during cyclosporin A treatment can regress spontaneously after cessation of immunosuppression.
3/2004	GM-CSF enhances protective immunity to cottontail rabbit papillomavirus E8 genetic vaccination in rabbits.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jiafen Hu Research Topics

Disease

17	Infections 01/2022 - 01/2006
12	Papilloma (Papillomatosis) 01/2021 - 07/2002
7	Papillomavirus Infections 01/2022 - 02/2007
6	Neoplasms (Cancer) 01/2022 - 07/2004
4	Virus Diseases (Viral Diseases) 01/2022 - 12/2002
2	Spontaneous Remission 04/2013 - 12/2002
2	Hypersensitivity (Allergy) 03/2004 - 07/2002
1	Herpes Simplex 01/2022
1	Condylomata Acuminata (Genital Wart) 01/2022
1	Disease Progression 01/2022
1	Hyperplasia 01/2021
1	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2021
1	Epstein-Barr Virus Infections 10/2020
1	Squamous Cell Carcinoma of Head and Neck 01/2020
1	Acquired Immunodeficiency Syndrome (AIDS) 01/2018
1	Coinfection 08/2013
1	Corneal Diseases (Corneal Disease) 03/2010

Drug/Important Bio-Agent (IBA)

7	Viral DNAIBA 01/2021 - 01/2006
7	DNA (Deoxyribonucleic Acid)IBA 01/2019 - 01/2006
5	VaccinesIBA 01/2022 - 02/2007
5	EpitopesIBA 02/2011 - 12/2006
4	Proteins (Proteins, Gene)FDA Link 01/2019 - 12/2002
3	Peptides (Polypeptides)IBA 01/2014 - 07/2002
3	Amino Acids FDA Link 01/2007 - 12/2002
2	RNA (Ribonucleic Acid)IBA 01/2021 - 01/2019
2	Cyclosporine (Ciclosporin)FDA LinkGeneric 10/2020 - 01/2005
2	Indicators and Reagents (Reagents)IBA 01/2017 - 08/2014
2	Codon (Codons)IBA 04/2013 - 08/2008
1	MedroxyprogesteroneIBA 01/2022
1	N,N-dimethyl-4-anisidine (DMPA)IBA 01/2022
1	DEPOIBA 01/2022
1	Contraceptive Agents (Contraceptives)IBA 01/2022
1	CarcinogensIBA 01/2021
1	SmokeIBA 01/2021
1	Viral ProteinsIBA 01/2021
1	Environmental Pollutants (Pollutants, Environmental)IBA 01/2021
1	dibenzo(a,l)pyreneIBA 01/2021
1	Biological ProductsIBA 01/2020
1	Virus-Like Particle VaccinesIBA 01/2019
1	Rabies Vaccines (Rabies Vaccine)FDA Link 01/2018
1	AntibodiesIBA 09/2014
1	Cidofovir (Vistide)FDA Link 08/2014
1	NucleosidesIBA 08/2014
1	Protein Subunit VaccinesIBA 01/2014
1	T-Lymphocyte Epitopes (Epitopes, T Lymphocyte)IBA 03/2010
1	HLA-A*02:01 antigenIBA 03/2010
1	DNA VaccinesIBA 02/2008
1	Monoclonal AntibodiesIBA 12/2007
1	AntigensIBA 02/2007
1	Capsid Proteins (Capsid Protein)IBA 01/2006
1	Neutralizing AntibodiesIBA 01/2006
1	Pharmaceutical PreparationsIBA 01/2005
1	AgarIBA 07/2004
1	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 03/2004
1	cottontail rabbit papillomavirus E8 proteinIBA 07/2002